{"id":14639,"date":"2025-10-06T15:59:22","date_gmt":"2025-10-06T10:29:22","guid":{"rendered":"https:\/\/www.torusdigital.com\/toruscope\/?p=14639"},"modified":"2025-10-06T15:59:22","modified_gmt":"2025-10-06T10:29:22","slug":"rubicon-research-ltd-ipo-opens-key-details-investors-shouldnt-miss","status":"publish","type":"post","link":"https:\/\/www.torusdigital.com\/toruscope\/news\/rubicon-research-ltd-ipo-opens-key-details-investors-shouldnt-miss\/","title":{"rendered":"Rubicon Research Ltd. IPO Opens: Key Details Investors Shouldn\u2019t Miss"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_section el_id=&#8221;blog-inner-layout&#8221;][vc_row overlay_dotted=&#8221;&#8221;][vc_column el_class=&#8221;blog_primary&#8221;][vc_row_inner][vc_column_inner][vc_column_text css=&#8221;&#8221;]<\/p>\n<p>India\u2019s IPO market in 2025 continues to witness participation from high-growth niche sectors. Among the standout offerings is Rubicon Research Limited, a pharmaceutical company with a strong global footprint, particularly in the US generics market. The company is set to open its IPO on October 9, 2025, offering investors a chance to participate in its expansion and strategic growth plans.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"About_Rubicon_Research_Ltd\"><\/span><strong>About Rubicon Research Ltd.<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Incorporated in 1999, Rubicon Research Limited is engaged in the development, manufacturing, and commercialisation of differentiated pharmaceutical formulations. As of June 30, 2025:<\/p>\n<ul>\n<li>The company has 72 active ANDA\/NDA products approved by the US FDA, of which 66 are commercialised.<\/li>\n<li>The US generic pharmaceutical market size is USD 2,455.7 million, with Rubicon contributing USD 195 million in FY2024.<\/li>\n<li>17 new products are awaiting US FDA ANDA approval, and 63 products are in various stages of development.<\/li>\n<li>Rubicon markets over 350 SKUs to 96 customers, with three major wholesalers accounting for more than 90% of US wholesale distribution.<\/li>\n<\/ul>\n<p>Beyond the US, the company has 48 product applications filed or registered in Australia, the UK, Singapore, Saudi Arabia, and the UAE, with plans to commence commercial activities upon approval. Rubicon also provides contract manufacturing services in India, Australia, and New Zealand.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Manufacturing_R_D_Facilities\"><\/span><strong>Manufacturing &amp; R&amp;D Facilities:<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<ul>\n<li>Three manufacturing facilities in India<\/li>\n<li>Two US FDA inspected R&amp;D centers (India &amp; Canada)<\/li>\n<\/ul>\n<h3><span class=\"ez-toc-section\" id=\"Competitive_Strengths\"><\/span><strong>Competitive Strengths:<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<ul>\n<li>Rapidly growing Indian pharmaceutical company among peers<\/li>\n<li>Data-driven product selection framework<\/li>\n<li>Strong R&amp;D capabilities<\/li>\n<li>Robust US sales and distribution network<\/li>\n<li>Strong compliance and cost-effective manufacturing<\/li>\n<li>Experienced and entrepreneurial management team<\/li>\n<\/ul>\n<p><a href=\"https:\/\/torusdigital.go.link\/hgQeE\" target=\"_blank\" rel=\"noopener\"><br \/>\n<img decoding=\"async\" class=\"responsive-img\" src=\"https:\/\/www.torusdigital.com\/toruscope\/wp-content\/uploads\/2025\/07\/Desktop-1.jpg\" alt=\"\" \/><br \/>\n<\/a><\/p>\n<style>\n  .responsive-img {<br \/>\n    display: block;<br \/>\n    margin-left: auto;<br \/>\n    margin-right: auto;<br \/>\n    width: 100%;<br \/>\n    max-width: 900px;<br \/>\n<\/style>\n<h2><span class=\"ez-toc-section\" id=\"Rubicon_Research_IPO_Details\"><\/span><strong>Rubicon Research IPO Details<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The <a href=\"https:\/\/www.torusdigital.com\/ipo\/rubicon-research-ltd-ipo\">Rubicon Research IPO<\/a> is a book-building issue of \u20b91,377.50 crore, combining a fresh issue of 1.03 crore shares (\u20b9500 Cr) and offer for sale of 1.81 crore shares (\u20b9877.50 Cr).<\/p>\n<h3><span class=\"ez-toc-section\" id=\"IPO_Timeline\"><\/span><strong>IPO Timeline:<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<table>\n<thead>\n<tr>\n<td><strong>Event<\/strong><\/td>\n<td><strong>Date (Tentative)<\/strong><\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>IPO Open Date<\/td>\n<td>Oct 9, 2025<\/td>\n<\/tr>\n<tr>\n<td>IPO Close Date<\/td>\n<td>Oct 13, 2025<\/td>\n<\/tr>\n<tr>\n<td>Tentative Allotment<\/td>\n<td>Oct 14, 2025<\/td>\n<\/tr>\n<tr>\n<td>Initiation of Refunds<\/td>\n<td>Oct 15, 2025<\/td>\n<\/tr>\n<tr>\n<td>Credit of Shares to Demat<\/td>\n<td>Oct 15, 2025<\/td>\n<\/tr>\n<tr>\n<td>Tentative Listing Date<\/td>\n<td>Oct 16, 2025<\/td>\n<\/tr>\n<tr>\n<td>Cut-off time for UPI mandate confirmation<\/td>\n<td>5 PM on Oct 13, 2025<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3><span class=\"ez-toc-section\" id=\"Key_IPO_Details\"><\/span><strong>Key IPO Details:<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<table>\n<thead>\n<tr>\n<td><strong>Parameter<\/strong><\/td>\n<td><strong>Details<\/strong><\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Face Value<\/td>\n<td>\u20b91 per share<\/td>\n<\/tr>\n<tr>\n<td>Issue Price Band<\/td>\n<td>\u20b9461 \u2013 \u20b9485 per share<\/td>\n<\/tr>\n<tr>\n<td>Lot Size<\/td>\n<td>30 shares<\/td>\n<\/tr>\n<tr>\n<td>Total Issue Size<\/td>\n<td>2.84 crore shares (\u20b91,377.50 Cr)<\/td>\n<\/tr>\n<tr>\n<td>Fresh Issue<\/td>\n<td>1.03 crore shares (\u20b9500 Cr)<\/td>\n<\/tr>\n<tr>\n<td>Offer for Sale<\/td>\n<td>1.81 crore shares (\u20b9877.50 Cr)<\/td>\n<\/tr>\n<tr>\n<td>Employee Discount<\/td>\n<td>\u20b946 per share<\/td>\n<\/tr>\n<tr>\n<td>Issue Type<\/td>\n<td>Bookbuilding IPO<\/td>\n<\/tr>\n<tr>\n<td>Listing At<\/td>\n<td>BSE, NSE<\/td>\n<\/tr>\n<tr>\n<td>Shareholding Pre-Issue<\/td>\n<td>15.44 crore shares<\/td>\n<\/tr>\n<tr>\n<td>Shareholding Post-Issue<\/td>\n<td>16.47 crore shares<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3><span class=\"ez-toc-section\" id=\"Investor_Category_Reservation\"><\/span><strong>Investor Category Reservation:<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<table>\n<thead>\n<tr>\n<td><strong>Investor Category<\/strong><\/td>\n<td><strong>Allocation<\/strong><\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>QIB<\/td>\n<td>Not less than 75% of Net Offer<\/td>\n<\/tr>\n<tr>\n<td>Retail<\/td>\n<td>Not more than 10% of Net Offer<\/td>\n<\/tr>\n<tr>\n<td>NII<\/td>\n<td>Not more than 15% of Net Offer<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3><span class=\"ez-toc-section\" id=\"Lot_Size_Investment\"><\/span><strong>Lot Size &amp; Investment:<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<table>\n<thead>\n<tr>\n<td><strong>Application<\/strong><\/td>\n<td><strong>Lots<\/strong><\/td>\n<td><strong>Shares<\/strong><\/td>\n<td><strong>Amount<\/strong><\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Retail (Min)<\/td>\n<td>1<\/td>\n<td>30<\/td>\n<td>\u20b914,550<\/td>\n<\/tr>\n<tr>\n<td>Retail (Max)<\/td>\n<td>13<\/td>\n<td>390<\/td>\n<td>\u20b91,89,150<\/td>\n<\/tr>\n<tr>\n<td>S-HNI (Min)<\/td>\n<td>14<\/td>\n<td>420<\/td>\n<td>\u20b92,03,700<\/td>\n<\/tr>\n<tr>\n<td>S-HNI (Max)<\/td>\n<td>68<\/td>\n<td>2,040<\/td>\n<td>\u20b99,89,400<\/td>\n<\/tr>\n<tr>\n<td>B-HNI (Min)<\/td>\n<td>69<\/td>\n<td>2,070<\/td>\n<td>\u20b910,03,950<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3><span class=\"ez-toc-section\" id=\"Promoter_Holding\"><\/span><strong>Promoter Holding:<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The promoters include General Atlantic Singapore RR Pte. Ltd., Pratibha Pilgaonkar, Sudhir Dhirendra Pilgaonkar, Parag Suganchand Sancheti, Surabhi Parag Sancheti, and Sumant Sudhir Pilgaonkar.<\/p>\n<ul>\n<li>Pre-IPO: 77.67%<\/li>\n<li>Post-IPO: [To be calculated based on equity dilution]<\/li>\n<\/ul>\n<p><strong>Book Running Lead Manager:<\/strong> Axis Capital Ltd.<br \/>\n<strong>Registrar:<\/strong> MUFG Intime India Pvt. Ltd.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Rubicon_Research_Ltd_Financials\"><\/span><strong>Rubicon Research Ltd.: Financials<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Financial_Highlights_%E2%82%B9_Crore\"><\/span><strong>Financial Highlights (\u20b9 Crore):<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<table>\n<thead>\n<tr>\n<td><strong>Period Ended<\/strong><\/td>\n<td><strong>30 Jun 2025<\/strong><\/td>\n<td><strong>31 Mar 2025<\/strong><\/td>\n<td><strong>31 Mar 2024<\/strong><\/td>\n<td><strong>31 Mar 2023<\/strong><\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Assets<\/td>\n<td>1,647.60<\/td>\n<td>1,451.43<\/td>\n<td>1,109.49<\/td>\n<td>749.70<\/td>\n<\/tr>\n<tr>\n<td>Total Income<\/td>\n<td>356.95<\/td>\n<td>1,296.22<\/td>\n<td>872.39<\/td>\n<td>419.00<\/td>\n<\/tr>\n<tr>\n<td>Profit After Tax<\/td>\n<td>43.30<\/td>\n<td>134.36<\/td>\n<td>91.01<\/td>\n<td>-16.89<\/td>\n<\/tr>\n<tr>\n<td>EBITDA<\/td>\n<td>79.74<\/td>\n<td>267.89<\/td>\n<td>173.09<\/td>\n<td>43.97<\/td>\n<\/tr>\n<tr>\n<td>Net Worth<\/td>\n<td>593.67<\/td>\n<td>540.98<\/td>\n<td>385.00<\/td>\n<td>286.38<\/td>\n<\/tr>\n<tr>\n<td>Reserves &amp; Surplus<\/td>\n<td>397.50<\/td>\n<td>525.57<\/td>\n<td>369.79<\/td>\n<td>281.31<\/td>\n<\/tr>\n<tr>\n<td>Total Borrowing<\/td>\n<td>495.78<\/td>\n<td>393.17<\/td>\n<td>396.41<\/td>\n<td>317.91<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3><span class=\"ez-toc-section\" id=\"Key_Performance_Indicators_FY2025\"><\/span><strong>Key Performance Indicators (FY2025):<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<table>\n<thead>\n<tr>\n<td><strong>KPI<\/strong><\/td>\n<td><strong>Value<\/strong><\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>ROE<\/td>\n<td>29.02%<\/td>\n<\/tr>\n<tr>\n<td>ROCE<\/td>\n<td>26.45%<\/td>\n<\/tr>\n<tr>\n<td>Debt\/Equity<\/td>\n<td>0.73<\/td>\n<\/tr>\n<tr>\n<td>RoNW<\/td>\n<td>29.02%<\/td>\n<\/tr>\n<tr>\n<td>PAT Margin<\/td>\n<td>10.37%<\/td>\n<\/tr>\n<tr>\n<td>EBITDA Margin<\/td>\n<td>20.67%<\/td>\n<\/tr>\n<tr>\n<td>EPS Pre-IPO<\/td>\n<td>\u20b98.70<\/td>\n<\/tr>\n<tr>\n<td>EPS Post-IPO<\/td>\n<td>[To be calculated]<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3><span class=\"ez-toc-section\" id=\"Rubicon_Research_IPO_Objectives\"><\/span><strong>Rubicon Research IPO Objectives<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The IPO proceeds are proposed to be utilised as follows:<\/p>\n<table>\n<thead>\n<tr>\n<td><strong>S.No<\/strong><\/td>\n<td><strong>Object<\/strong><\/td>\n<td><strong>Expected Amount (\u20b9 Million)<\/strong><\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Prepayment or scheduled repayment of outstanding borrowings<\/td>\n<td>3,100<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Funding inorganic growth via acquisitions and general corporate purposes<\/td>\n<td>Balance<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Rubicon_Research_IPO_Peer_Comparison\"><\/span><strong>Rubicon Research IPO: Peer Comparison<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Rubicon Research IPO can be compared with peers like <a href=\"https:\/\/www.torusdigital.com\/stocks\/aurobindo-pharma-ltd-share-price\">Aurobindo Pharma Ltd<\/a>, <a href=\"https:\/\/www.torusdigital.com\/stocks\/laurus-labs-ltd-share-price\">Laurus Labs Ltd<\/a>, Cipla Ltd, Sun Pharmaceutical Industries Ltd, and Dr Reddy\u2019s Laboratories Ltd. Reviewing these companies helps investors gauge Rubicon Research\u2019s position in the pharmaceutical sector and make informed investment decisions.<\/p>\n<p><strong>Also Read:<\/strong><\/p>\n<ul>\n<li><a href=\"https:\/\/www.torusdigital.com\/toruscope\/news\/anantam-highways-invit-ipo-opens-key-details-investors-shouldnt-miss\/\">Anantam Highways InvIT IPO Opens: Key Details Investors Shouldn\u2019t Miss<\/a><\/li>\n<li><a href=\"https:\/\/www.torusdigital.com\/toruscope\/news\/mittal-sections-ltd-ipo-opens-key-details-investors-shouldnt-miss\/\">Mittal Sections Ltd. IPO Opens: Key Details Investors Shouldn\u2019t Miss<\/a><\/li>\n<li><a href=\"https:\/\/www.torusdigital.com\/toruscope\/news\/lg-electronics-india-ipo-opens-key-details-investors-shouldnt-miss\/\">LG Electronics India IPO Opens: Key Details Investors Shouldn\u2019t Miss<\/a><\/li>\n<li><a href=\"https:\/\/www.torusdigital.com\/toruscope\/news\/tata-capital-ltd-ipo-opens-key-details-investors-shouldnt-miss\/\">Tata Capital Ltd. IPO Opens: Key Details Investors Shouldn\u2019t Miss<\/a><\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Rubicon Research Ltd. offers investors exposure to a fast-growing Indian pharmaceutical company with strong US and global market presence. Its robust R&amp;D, compliance track record, and strategic expansion plans make it a compelling opportunity. However, potential investors should consider risks such as regulatory approvals, dependency on key customers, and market competition before investing.<\/p>\n<p>If you are exploring more investment opportunities, check out our dedicated page on <a href=\"https:\/\/www.torusdigital.com\/ipo\/upcoming-ipo\">upcoming IPO listings<\/a> to stay updated on the latest market offerings.<\/p>\n<p>[\/vc_column_text][\/vc_column_inner][vc_column_inner width=&#8221;1\/2&#8243;][vc_column_text css=&#8221;&#8221;][\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_id=&#8221;share_rating&#8221;][vc_column_inner width=&#8221;1\/2&#8243;][vc_column_text css=&#8221;&#8221;]<\/p>\n<h6>Rate this article<\/h6>\n<!-- FeedbackWP Plugin --><div  class=\"rmp-widgets-container rmp-wp-plugin rmp-main-container js-rmp-widgets-container js-rmp-widgets-container--14639 \"  data-post-id=\"14639\">    <!-- Rating widget -->  <div class=\"rmp-rating-widget js-rmp-rating-widget\">            <div class=\"rmp-rating-widget__icons\">      <ul class=\"rmp-rating-widget__icons-list js-rmp-rating-icons-list\">                  <li class=\"rmp-rating-widget__icons-list__icon js-rmp-rating-item\" data-descriptive-rating=\"Terrible!\" data-value=\"1\">              <i class=\"js-rmp-rating-icon rmp-icon rmp-icon--ratings rmp-icon--star \"><\/i>          <\/li>                  <li class=\"rmp-rating-widget__icons-list__icon js-rmp-rating-item\" data-descriptive-rating=\"Bad!\" data-value=\"2\">              <i class=\"js-rmp-rating-icon rmp-icon rmp-icon--ratings rmp-icon--star \"><\/i>          <\/li>                  <li class=\"rmp-rating-widget__icons-list__icon js-rmp-rating-item\" data-descriptive-rating=\"Okay!\" data-value=\"3\">              <i class=\"js-rmp-rating-icon rmp-icon rmp-icon--ratings rmp-icon--star \"><\/i>          <\/li>                  <li class=\"rmp-rating-widget__icons-list__icon js-rmp-rating-item\" data-descriptive-rating=\"Good!\" data-value=\"4\">              <i class=\"js-rmp-rating-icon rmp-icon rmp-icon--ratings rmp-icon--star \"><\/i>          <\/li>                  <li class=\"rmp-rating-widget__icons-list__icon js-rmp-rating-item\" data-descriptive-rating=\"Great!\" data-value=\"5\">              <i class=\"js-rmp-rating-icon rmp-icon rmp-icon--ratings rmp-icon--star \"><\/i>          <\/li>              <\/ul>    <\/div>    <p class=\"rmp-rating-widget__hover-text js-rmp-hover-text\"><\/p>    <button class=\"rmp-rating-widget__submit-btn rmp-btn js-submit-rating-btn\">      Submit Rating    <\/button>    <p class=\"rmp-rating-widget__results js-rmp-results rmp-rating-widget__results--hidden\">       <span class=\"rmp-rating-widget__results__rating js-rmp-avg-rating\">0<\/span> \/ 5.  <span class=\"rmp-rating-widget__results__votes js-rmp-vote-count\">0<\/span>    <\/p>    <p class=\"rmp-rating-widget__not-rated js-rmp-not-rated \">          <\/p>    <p class=\"rmp-rating-widget__msg js-rmp-msg\"><\/p>  <\/div>  <!--Structured data -->        <\/div>\n<div id=\"emoji-overlay\" style=\"display: none;\">\n<div id=\"overlay-emoji\"><\/div>\n<div id=\"overlay-description\" class=\"emoji-text\"><\/div>\n<\/div>\n<div id=\"rating-popup\">\n<p><span id=\"popup-close\">\u00d7<\/span><\/p>\n<div class=\"popup_message\">\n<div id=\"popup-emoji\"><\/div>\n<div class=\"popup_innermsg\">\n<h5>Thank You for Rating Our Article!<\/h5>\n<p>Your feedback is incredibly valuable to us, and we&#8217;re thrilled to hear your thoughts.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<p>[\/vc_column_text][\/vc_column_inner][vc_column_inner width=&#8221;1\/2&#8243;][vc_column_text css=&#8221;&#8221;]<\/p>\n<h6>Share this article<\/h6>\n<div class=\"cscra-social square cscra-socials-679c8a1122c00\">\n        <a href=\"\/\/www.facebook.com\/sharer\/sharer.php?u=https%3A%2F%2Fwww.torusdigital.com%2Ftoruscope%2Fnews%2Frubicon-research-ltd-ipo-opens-key-details-investors-shouldnt-miss%2F&t=Rubicon+Research+Ltd.+IPO+Opens%3A+Key+Details+Investors+Shouldn%E2%80%99t+Miss\" class=\"facebook\" data-toggle=\"tooltip\" data-placement=\"top\" title=\"Share On Facebook\" target=\"_blank\"><i class=\"fa fa-facebook\"><\/i><\/a>\n        <a href=\"\/\/twitter.com\/intent\/tweet?text=Rubicon+Research+Ltd.+IPO+Opens%3A+Key+Details+Investors+Shouldn%E2%80%99t+Miss&url=https%3A%2F%2Fwww.torusdigital.com%2Ftoruscope%2Fnews%2Frubicon-research-ltd-ipo-opens-key-details-investors-shouldnt-miss%2F\" class=\"twitter\" data-toggle=\"tooltip\" data-placement=\"top\" title=\"Share On Twitter\" target=\"_blank\"><i class=\"fa-brands fa-x-twitter\"><\/i><\/a>\n        <a href=\"https:\/\/api.whatsapp.com\/send?text=Rubicon+Research+Ltd.+IPO+Opens%3A+Key+Details+Investors+Shouldn%E2%80%99t+Miss - https%3A%2F%2Fwww.torusdigital.com%2Ftoruscope%2Fnews%2Frubicon-research-ltd-ipo-opens-key-details-investors-shouldnt-miss%2F\" class=\"whatsapp\" data-toggle=\"tooltip\" data-placement=\"top\" title=\"Share On WhatsApp\" target=\"_blank\"><i class=\"fa fa-whatsapp\"><\/i><\/a>\n        <a href=\"\/\/www.linkedin.com\/shareArticle?mini=true&url=https%3A%2F%2Fwww.torusdigital.com%2Ftoruscope%2Fnews%2Frubicon-research-ltd-ipo-opens-key-details-investors-shouldnt-miss%2F&title=Rubicon+Research+Ltd.+IPO+Opens%3A+Key+Details+Investors+Shouldn%E2%80%99t+Miss\" class=\"linkedin\" data-toggle=\"tooltip\" data-placement=\"top\" title=\"Share On Linkedin\" target=\"_blank\"><i class=\"fa fa-linkedin\"><\/i><\/a>\n    <\/div>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][\/vc_section]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"[vc_section el_id=&#8221;blog-inner-layout&#8221;][vc_row overlay_dotted=&#8221;&#8221;][vc_column el_class=&#8221;blog_primary&#8221;][vc_row_inner][vc_column_inner][vc_column_text css=&#8221;&#8221;] India\u2019s IPO market in 2025 continues to witness participation from high-growth niche sectors. Among the standout offerings is Rubicon Research Limited, a pharmaceutical company with a strong global footprint, particularly in the US generics market. The company is set to open its IPO on October 9, 2025, offering investors a","protected":false},"author":1,"featured_media":14110,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_sitemap_exclude":false,"_sitemap_priority":"","_sitemap_frequency":"","footnotes":""},"categories":[5,169],"tags":[],"class_list":["post-14639","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-ipo","category-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Rubicon Research IPO Opens: Key Details Investors Must Know<\/title>\n<meta name=\"description\" content=\"Rubicon Research IPO offers investors an opportunity to invest in a leading Indian pharmaceutical company with a strong US and global presence. Check key IPO details and financials here.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.torusdigital.com\/toruscope\/news\/rubicon-research-ltd-ipo-opens-key-details-investors-shouldnt-miss\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Rubicon Research IPO Opens: Key Details Investors Must Know\" \/>\n<meta property=\"og:description\" content=\"Rubicon Research IPO offers investors an opportunity to invest in a leading Indian pharmaceutical company with a strong US and global presence. Check key IPO details and financials here.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.torusdigital.com\/toruscope\/news\/rubicon-research-ltd-ipo-opens-key-details-investors-shouldnt-miss\/\" \/>\n<meta property=\"og:site_name\" content=\"Blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-06T10:29:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.torusdigital.com\/toruscope\/wp-content\/uploads\/2025\/08\/Aditya-Infotech-Ltd-Mainboard-IPO.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1441\" \/>\n\t<meta property=\"og:image:height\" content=\"466\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"torus\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"torus\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Rubicon Research IPO Opens: Key Details Investors Must Know","description":"Rubicon Research IPO offers investors an opportunity to invest in a leading Indian pharmaceutical company with a strong US and global presence. Check key IPO details and financials here.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.torusdigital.com\/toruscope\/news\/rubicon-research-ltd-ipo-opens-key-details-investors-shouldnt-miss\/","og_locale":"en_US","og_type":"article","og_title":"Rubicon Research IPO Opens: Key Details Investors Must Know","og_description":"Rubicon Research IPO offers investors an opportunity to invest in a leading Indian pharmaceutical company with a strong US and global presence. Check key IPO details and financials here.","og_url":"https:\/\/www.torusdigital.com\/toruscope\/news\/rubicon-research-ltd-ipo-opens-key-details-investors-shouldnt-miss\/","og_site_name":"Blog","article_published_time":"2025-10-06T10:29:22+00:00","og_image":[{"width":1441,"height":466,"url":"https:\/\/www.torusdigital.com\/toruscope\/wp-content\/uploads\/2025\/08\/Aditya-Infotech-Ltd-Mainboard-IPO.webp","type":"image\/webp"}],"author":"torus","twitter_card":"summary_large_image","twitter_misc":{"Written by":"torus","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.torusdigital.com\/toruscope\/news\/rubicon-research-ltd-ipo-opens-key-details-investors-shouldnt-miss\/","url":"https:\/\/www.torusdigital.com\/toruscope\/news\/rubicon-research-ltd-ipo-opens-key-details-investors-shouldnt-miss\/","name":"Rubicon Research IPO Opens: Key Details Investors Must Know","isPartOf":{"@id":"https:\/\/www.torusdigital.com\/toruscope\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.torusdigital.com\/toruscope\/news\/rubicon-research-ltd-ipo-opens-key-details-investors-shouldnt-miss\/#primaryimage"},"image":{"@id":"https:\/\/www.torusdigital.com\/toruscope\/news\/rubicon-research-ltd-ipo-opens-key-details-investors-shouldnt-miss\/#primaryimage"},"thumbnailUrl":"https:\/\/www.torusdigital.com\/toruscope\/wp-content\/uploads\/2025\/08\/Aditya-Infotech-Ltd-Mainboard-IPO.webp","datePublished":"2025-10-06T10:29:22+00:00","author":{"@id":"https:\/\/www.torusdigital.com\/toruscope\/#\/schema\/person\/468d817c6d51cdd85d58071858a47ce5"},"description":"Rubicon Research IPO offers investors an opportunity to invest in a leading Indian pharmaceutical company with a strong US and global presence. Check key IPO details and financials here.","breadcrumb":{"@id":"https:\/\/www.torusdigital.com\/toruscope\/news\/rubicon-research-ltd-ipo-opens-key-details-investors-shouldnt-miss\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.torusdigital.com\/toruscope\/news\/rubicon-research-ltd-ipo-opens-key-details-investors-shouldnt-miss\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.torusdigital.com\/toruscope\/news\/rubicon-research-ltd-ipo-opens-key-details-investors-shouldnt-miss\/#primaryimage","url":"https:\/\/www.torusdigital.com\/toruscope\/wp-content\/uploads\/2025\/08\/Aditya-Infotech-Ltd-Mainboard-IPO.webp","contentUrl":"https:\/\/www.torusdigital.com\/toruscope\/wp-content\/uploads\/2025\/08\/Aditya-Infotech-Ltd-Mainboard-IPO.webp","width":1441,"height":466},{"@type":"BreadcrumbList","@id":"https:\/\/www.torusdigital.com\/toruscope\/news\/rubicon-research-ltd-ipo-opens-key-details-investors-shouldnt-miss\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Toruscope","item":"https:\/\/www.torusdigital.com\/toruscope\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/www.torusdigital.com\/toruscope\/.\/news\/"},{"@type":"ListItem","position":3,"name":"Rubicon Research Ltd. IPO Opens: Key Details Investors Shouldn\u2019t Miss"}]},{"@type":"WebSite","@id":"https:\/\/www.torusdigital.com\/toruscope\/#website","url":"https:\/\/www.torusdigital.com\/toruscope\/","name":"Blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.torusdigital.com\/toruscope\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.torusdigital.com\/toruscope\/#\/schema\/person\/468d817c6d51cdd85d58071858a47ce5","name":"torus","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.torusdigital.com\/toruscope\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/09645f2c6ef6bbb3a78db22600040d547bed4438a393e0671d168d69d193bc19?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/09645f2c6ef6bbb3a78db22600040d547bed4438a393e0671d168d69d193bc19?s=96&d=mm&r=g","caption":"torus"},"sameAs":["https:\/\/stage.torusdigital.com\/blogs"],"url":"https:\/\/www.torusdigital.com\/toruscope\/author\/torus\/"}]}},"_links":{"self":[{"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/posts\/14639","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/comments?post=14639"}],"version-history":[{"count":1,"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/posts\/14639\/revisions"}],"predecessor-version":[{"id":14640,"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/posts\/14639\/revisions\/14640"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/media\/14110"}],"wp:attachment":[{"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/media?parent=14639"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/categories?post=14639"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.torusdigital.com\/toruscope\/wp-json\/wp\/v2\/tags?post=14639"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}